Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk

References

• AmielSAHellerSRMacdonaldIAThe effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetesDiabetes Obes Metab200575041616050943
   PubMed Web of Science ®Google Scholar
• BaronADKimDWeyerCNovel peptides under development for the treatment of type 1 and type 2 diabetes mellitusCurr Drug Targets Immune Endocr Metabol Disord20022638212477297
   PubMedGoogle Scholar
• BlondeLKleinEJHanJInterim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetesDiabetes Obes Metab200684364716776751
   PubMed Web of Science ®Google Scholar
• CerielloAKumarSPiconiLSimultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetesDiabetes Care2007306495417327335
   PubMed Web of Science ®Google Scholar
• CerielloAPiconiLQuagliaroLEffects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetesDiabetes Care200528632715735200
   PubMed Web of Science ®Google Scholar
• ChapmanIParkerBDoranSEffect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetesDiabetologia2005488384815843914
   PubMed Web of Science ®Google Scholar
• DCCT Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research GroupN Engl J Med1993329977868366922
   PubMed Web of Science ®Google Scholar
• DCCT Research GroupInfluence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications TrialDiabetes Care20012417112111574431
   PubMed Web of Science ®Google Scholar
• DCCT/EDIC Research GroupRetinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupN Engl J Med2000342381910666428
   PubMedGoogle Scholar
• EdelmanSGargSFriasJA double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetesDiabetes Care20062921899517003291
   PubMed Web of Science ®Google Scholar
• FinemanMBahnerAGottliebAEffects of six months of administration of pramlintide as an adjunct to insulin therapy on metabolic control in people wtih type 1 diabetesDiabetes1999a48Suppl 1A113
   Google Scholar
• FinemanMGottliebABahnerAPramlintide therapy in addition to insulin in type 1 diabetes: effect on metabolic control after 6 monthsDiabetologia1999b42A232 abstract 0872
   Google Scholar
• FinemanMWeyerCMaggsDGThe human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitusHorm Metab Res2002a34504812384827
   PubMed Web of Science ®Google Scholar
• FinemanMSKodaJEShenLZThe human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetesMetabolism2002b516364111979398
   PubMed Web of Science ®Google Scholar
• GedulinBRRinkTJYoungAADose-response for glucagonostatic effect of amylin in ratsMetabolism19974667709005972
   PubMed Web of Science ®Google Scholar
• GhiselliASerafiniMMaianiGA fluorescence-based method for measuring total plasma antioxidant capabilityFree Radic Biol Med19951829367896168
   PubMed Web of Science ®Google Scholar
• GiuglianoDCerielloAPaolissoGOxidative stress and diabetic vascular complicationsDiabetes Care199619257678742574
   PubMed Web of Science ®Google Scholar
• GottliebAVelteMFinemanMPramlintide as an adjunct to insuln therapy improved glycemic and weight control in people with type1 diabetes during treatment for 52 weeksDiabetes200049Suppl 1A109
   Google Scholar
• GottliebAFinemanMBahnerAPramlintide therapy in addition to insulin in type 2 diabetes: effect on metabolic control after 6 monthsDiabetologia200742SupplA232
   Google Scholar
• HalfordJCObesity drugs in clinical developmentCurr Opin Investig Drugs2006731218
   PubMed Web of Science ®Google Scholar
• HazenSLOxidation and atherosclerosisFree Radic Biol Med2000281683410946209
   PubMed Web of Science ®Google Scholar
• HeptullaRARodriguezLMBomgaarsLThe role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetesDiabetes2005541100715793249
   PubMed Web of Science ®Google Scholar
• HollanderPMaggsDGRugglesJAEffect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patientsObes Res200412661815090634
   PubMedGoogle Scholar
• HollanderPRatnerRFinemanMAddition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targetsDiabetes Obes Metab2003a54081414617226
   PubMed Web of Science ®Google Scholar
• HollanderPALevyPFinemanMSPramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trialDiabetes Care2003b267849012610038
   PubMed Web of Science ®Google Scholar
• HoogwerfBJExenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitusCleve Clin J Med2006734778416708716
   PubMed Web of Science ®Google Scholar
• HussarDANew drugs: exenatide, pramlintide acetate, and micafungin sodiumJ Am Pharm Assoc (2003)200545524716128511
   PubMed Web of Science ®Google Scholar
• KailasamMTParmerRJTyrellEACirculating amylin in human essential hypertension: heritability and early increase in individuals at genetic riskJ Hypertens20001816112011081774
   PubMed Web of Science ®Google Scholar
• KleppingerELVivianEMPramlintide for the treatment of diabetes mellitusAnn Pharmacother2003371082912841822
   PubMed Web of Science ®Google Scholar
• KoltermanOGGottliebAMoysesCReduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogueDiabetes Care1995181179827587855
   PubMed Web of Science ®Google Scholar
• KoltermanOGSchwartzSCorderCEffect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDMDiabetologia19963949298778001
   PubMed Web of Science ®Google Scholar
• KongMFStubbsTAKingPThe effect of single doses of pramlintide on gastric emptying of two meals in men with IDDMDiabetologia199841577839628276
   PubMed Web of Science ®Google Scholar
• LevetanCWantLLWeyerCImpact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumpsDiabetes Care2003261812502651
   PubMed Web of Science ®Google Scholar
• LutzTADelPEScharrerESubdiaphragmatic vagotomy does not influence the anorectic effect of amylinPeptides199516457627651899
   PubMed Web of Science ®Google Scholar
• MarreroDGCreanJZhangBEffect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetesDiabetes Care2007302101617259483
   PubMed Web of Science ®Google Scholar
• NichollsSJHazenSLThe role of myeloperoxidase in the pathogenesis of coronary artery diseaseJpn J Infect Dis200457S21S2215507760
   PubMed Web of Science ®Google Scholar
• NichollsSJHazenSLMyeloperoxidase and cardiovascular diseaseArterioscler Thromb Vasc Biol20052511021115790935
   PubMed Web of Science ®Google Scholar
• NogidAPhamDQAdjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitusPharmacotherapy20062616264017064208
   PubMed Web of Science ®Google Scholar
• NyholmBOrskovLHoveKYThe amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patien ts with type 1 diabetes mellitusMetabolism1999489354110421239
   PubMed Web of Science ®Google Scholar
• PurnellJQWeyerCWeight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesityTreat Endocrinol20032334715871553
   PubMedGoogle Scholar
• RatnerRWhitehouseFFinemanMSAdjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targetsExp Clin Endocrinol Diabetes200511319920415891954
   PubMed Web of Science ®Google Scholar
• RatnerREDickeyRFinemanMAmylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trialDiabet Med20042112041215498087
   PubMed Web of Science ®Google Scholar
• RatnerREWantLLFinemanMSAdjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetesDiabetes Technol Ther20024516112017421
   PubMedGoogle Scholar
• RothJDHughesHKendallEAntiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expressionEndocrinology200614758556416935845
   PubMed Web of Science ®Google Scholar
• RyanGJJobeLJMartinRPramlintide in the treatment of type 1 and type 2 diabetes mellitusClin Ther20052715001216330288
   PubMed Web of Science ®Google Scholar
• SchmitzOBrockBRungbyJAmylin agonists: a novel approach in the treatment of diabetesDiabetes200453Suppl 3S233S815561917
   PubMed Web of Science ®Google Scholar
• ShahPVellaABasuALack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitusJ Clin Endocrinol Metab2000854053911095432
   PubMed Web of Science ®Google Scholar
• ShishehborMHAvilesRJBrennanMLAssociation of nitrotyrosine levels with cardiovascular disease and modulation by statin therapyJAMA200328916758012672736
   PubMed Web of Science ®Google Scholar
• ThompsonRGPearsonLKoltermanOGEffects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrationsDiabetologia1997a401278859389419
   PubMed Web of Science ®Google Scholar
• ThompsonRGPearsonLSchoenfeldSLPramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes GroupDiabetes Care199821987939614619
   PubMed Web of Science ®Google Scholar
• ThompsonRGPetersonJGottliebAEffects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trialDiabetes1997b4663269075803
   PubMed Web of Science ®Google Scholar
• UKPDS Research GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) GroupLancet1998a35285465
   PubMed Web of Science ®Google Scholar
• UKPDS Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet1998b35283753
   PubMed Web of Science ®Google Scholar
• UwaifoGIRatnerRENovel pharmacologic agents for type 2 diabetesEndocrinol Metab Clin North Am2005341559715752927
   PubMed Web of Science ®Google Scholar
• VellaALeeJSCamilleriMEffects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitusNeurogastroenterol Motil2002141233111975712
   PubMed Web of Science ®Google Scholar
• WantLUse of pramlintide: the patient's perspectiveDiabetes Educ200632Suppl 3111S18S16751352
   PubMedGoogle Scholar
• WantLLRatnerREPramlintide: A new tool in diabetes managementCurr Diab Rep20066344917076994
   PubMedGoogle Scholar
• WeyerCFinemanMSStrobelSProperties of pramlintide and insulin upon mixingAm J Health Syst Pharm2005628162215821274
   PubMed Web of Science ®Google Scholar
• WeyerCGottliebAKimDDPramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing studyDiabetes Care2003263074914578242
   PubMed Web of Science ®Google Scholar
• WeyerCMaggsDGYoungAAAmylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic controlCurr Pharm Des2001713537311472273
   PubMed Web of Science ®Google Scholar
• WhitehouseFKrugerDFFinemanMA randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetesDiabetes Care2002257243011919132
   PubMed Web of Science ®Google Scholar
• YoungATissue expression and secretion of amylinAdv Pharmacol200552194516492539
   PubMedGoogle Scholar
• YoungAKoltermanOHallJAmylin innocent in essential hypertension?Diabetologia199942102910491767
   PubMed Web of Science ®Google Scholar